AstraZeneca: FDA approves Calquence for LCM
(CercleFinance.com) - AstraZeneca reports that its Calquence, in combination with bendamustine and rituximab, has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
This approval was granted by the FDA after a priority review, and based on the results of the phase III ECHO trial, which showed more than 16 months' improvement in progression-free survival compared with chemoimmunotherapy alone.
It is estimated that over 21,000 patients have been diagnosed with MCL in the USA, UK, France, Germany, Spain, Italy, Japan and China, the British pharmaceutical company says.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
This approval was granted by the FDA after a priority review, and based on the results of the phase III ECHO trial, which showed more than 16 months' improvement in progression-free survival compared with chemoimmunotherapy alone.
It is estimated that over 21,000 patients have been diagnosed with MCL in the USA, UK, France, Germany, Spain, Italy, Japan and China, the British pharmaceutical company says.
Copyright (c) 2025 CercleFinance.com. All rights reserved.